<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141246">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01922583</url>
  </required_header>
  <id_info>
    <org_study_id>CAUY922ATW02T(201302063MIPD)</org_study_id>
    <secondary_id>1020009413</secondary_id>
    <nct_id>NCT01922583</nct_id>
  </id_info>
  <brief_title>AUY922 in Patient With Stage IV NSCLC</brief_title>
  <acronym>NSCLC</acronym>
  <official_title>A Multi-center Phase II Study of AUY922 in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed After One Line of Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, multicenter phase II trial in patients with stage IV EGFR
      T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged
      NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      This is an open-label, single-arm, multicenter phase II trial in patients with stage IV EGFR
      T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged
      NSCLC (n = 9 x 7)

      Objectives:

      Primary objective(s):

      To define the objective response rate by RECIST 1.1 of AUY922 in patients with stage IV EGFR
      T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged
      NSCLC

      Secondary objective(s):

      (1) To define the disease control rate (complete response + partial response + stable
      disease &gt;=24 weeks) of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other
      uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC. (2) To determine the
      progression-free survival of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and
      other uncommon, HER2, KRAS, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC. (3) To
      determine the overall survival of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20
      and other uncommon, HER2, KRAS, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC.

      Exploratory Objective(s):

      To study the pharmacodynamics of circulating tumor cells and plasma proteins.

      Planned number of subjects: A total of 63 patients for the first stage of this study in 1 -
      3 centers in Taiwan.

      Patient population:

        1. Stage IV (by AJCC 7th edition) NSCLC.

        2. EGFR T790M mutation; EGFR exon 20 and other uncommon mutation; HER2 mutation; BRAF
           mutation; ALK translocation; ROS1 translocation; or RET translocation in tumor samples.

        3. One line of prior systemic therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Patients will be followed up for 2 years(post disease progression)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To define the by RECIST 1.1 of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Patients will be followed up for PFS and OS for 2 years.(post disease progression)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will be followed for progression-free survival (PFS) and overall survival (OS) which will be analyzed by using a Kaplan-Meier curve.
Patients will be followed up for PFS and OS for 2 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Vial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AUY922</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AUY922</intervention_name>
    <description>AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression</description>
    <arm_group_label>Vial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven diagnosis of stage IV NSCLC (AJCC 7th) which
             had been treated with one systemic therapy.

          -  One of the molecular alterations as follows:

               -  EGFR mutations in exon 20 T790M.

               -  EGFR mutations in exon 20; in-frame duplication and/or insertion (e.g.
                  A767_V769dupASV or H773_V774insH) or point mutations other than T790M; or other
                  uncommon mutations.

               -  HER2 mutation in exon 20; in-frame duplication and/or insertion (e.g. YVMA
                  776-779 ins).

               -  BRAF mutation in exon 15; point mutation (e.g. V600E) or in exon 11; point
                  mutation (e.g. G469A, D594G).

               -  ALK translocation resulting in EML4-ALK, KIF5B-ALK, or TFG-ALK fusion as
                  determined by an ALK break apart FISH assay and defined by an increase in the
                  distance of 5' and 3' ALK probes (split 5'-3') or the loss of the 5' probe
                  (single 3'). Positive ALK results from other methods such as
                  immunohistochemistry (IHC) or reverse transcriptase polymerase chain reaction
                  testing may also be acceptable.

               -  ROS1 translocation resulting in CD74-ROS1 or SLC34A2-ROS1, etc.

               -  RET translocation resulting in KIF5B-RET fusion, etc.

          -  Patients with brain metastases are eligible if treated and neurologically stable for
             at least 2 weeks and is not taking any steroid.

          -  Any prior chemotherapy, targeted therapy (monoclonal antibodies), or major surgeries
             must have had completed at least 4 weeks before initiation of study medication. Any
             prior targeted therapy (tyrosine kinase inhibitors), radiotherapy or minor surgeries
             must have had completed at least 2 weeks before initiation of study medication. Any
             acute toxicity must have recovered to &lt;=grade 1 (except for alopecia).

          -  Patients must have measurable or evaluable disease as per RECIST version 1.1.

          -  20 years of age or older

          -  ECOG performance status 0-2

          -  Adequate organ function as defined by the following criteria:

               -  Bone marrow function

               -  Hemoglobin &gt;=8.0 g/dL

               -  Absolute neutrophil count (ANC) &gt;=1500/uL

               -  Platelets &gt;=100,000/uL

               -  Hepatic function

               -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) &lt;=3.0 x
                  upper limit of normal (ULN) or AST and ALT &lt;=5.0 x ULN if there is liver
                  metastasis

               -  Total serum bilirubin &lt;=1.5 x ULN Renal function

               -  Creatinine &lt;= 1.5 x ULN or creatinine clearance &gt;=45 mL/min

          -  Able to communicate well with the investigator, to understand and comply with the
             requirements of the study. Understand and sign the written informed consent.

          -  Patients must use effective methods of contraception during the study period and for
             at least 90 days following study completion (excluding surgically sterile male
             patients, surgically sterile or postmenopausal female patients).

        Exclusion Criteria:

          -  Currently on other therapeutic clinical trials

          -  Prior treatment of HSP90 inhibitors

          -  Any of the following within 3 months before initiation of study medication

               -  Myocardial infarction

               -  Unstable angina

               -  Coronary artery bypass graft

               -  Congestive heart failure NYHA functional class III or IV

               -  Cerebral vascular accident

               -  Transient ischemic attack

               -  Uncontrolled hypertension at screening

          -  Ongoing cardiac arrhythmias of NCI CTCAE grade &gt;=2

          -  Active infection requiring antibiotics

          -  Pregnancy or breast feeding

          -  Prior malignancy within the past 5 years (excluding non-melanoma skin cancer,
             cervical carcinoma in situ, superficial bladder cancer, and early prostate cancer).

          -  Active hepatitis B or C; positive HIV test result.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Hsin Yang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chih-Hsin Yang, MD, PhD</last_name>
    <phone>+886 23123456</phone>
    <phone_ext>67511</phone_ext>
    <email>chihyang@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anjeli Lin, BA</last_name>
    <phone>+886 23123456</phone>
    <phone_ext>66588</phone_ext>
    <email>anjeli@ntuh.gov.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wu-Chou Su, MD</last_name>
      <phone>+886 6 2353535</phone>
      <phone_ext>3120</phone_ext>
      <email>sunnysu@mail.ncku.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Wu-Chou Su, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen-Pin Su, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Min Yeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shang-Yin Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Chih-Hsin, M.D.,Ph.D.</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>67511</phone_ext>
      <email>chihyang@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>James Chih-Hsin Yang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kuan-Yu Chen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chao-Chi Ho, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josh Chia-Chi Lin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin-Yuan Shih, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chong-Jen Yu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Lin Lin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei-Yu Liao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jih-Hsiang Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tzu-Hsiu Tsai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei-Hsun Hsu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chun-Ming Tsai, MD</last_name>
      <phone>+886 2 28712121</phone>
      <phone_ext>2872</phone_ext>
      <email>cmtsai@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Chun-Ming Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuh-Min Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chao-Hua Chiu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC, EGFR mutation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
